Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

Guillaume Paré, Shamir R Mehta, Salim Yusuf, Sonia S Anand, Stuart J Connolly, Jack Hirsh, Katy Simonsen, Deepak L Bhatt, Keith A A Fox, John W Eikelboom

Research output: Contribution to journalArticlepeer-review


It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced conversion of clopidogrel to its active metabolite.
Original languageEnglish
Pages (from-to)1704-14
Number of pages11
JournalNew England Journal of Medicine
Issue number18
Publication statusPublished - 2010


Dive into the research topics of 'Effects of CYP2C19 genotype on outcomes of clopidogrel treatment'. Together they form a unique fingerprint.

Cite this